Product Images Finasteride

This table presents drug-related adverse experiences of Finasteride tablets, 1 mg for male pattern hair loss. The adverse experiences include decreased libido, erectile dysfunction, ejaculation disorder (decreased volume of ejaculate), and discontinuation due to drug-related sexual adverse experiences. The study included 945 participants in one year.*

The table provides the mean (SD) pharmacokinetic parameters in healthy men aged between 18-26. The data shows the mean bioavailability % (ranging from 26-170%), clearance (165 mL/min), and volume of distribution (76 L).*

This is a table showing the mean noncompartmental pharmacokinetic parameters in healthy men (ages 19-42) after multiple doses of 1 mg/day. The table presents values for AUC, peak concentration, time to peak and half-life. The mean AUC value is 53 ng hr/mL with a standard deviation of 33.8. The mean peak concentration is 220 ng/m. The mean time to peak is 13 hours with a standard deviation of 05 hours. The mean half-life value is 15 hours with a standard deviation of 1.6. The first dose is excluded from the half-life calculation.*

This text shows a table presenting the results of a study on the effect of a drug on hair count. It shows the mean number of hairs in a 1-inch diameter circle at different time points, the mean change in hair count from baseline, and the standard error. The study compared the effects of finasteride to a placebo. The data is presented for different groups of participants and time points.*

This is a medication called Finasteride, which is available in a film-coated tablet format. Each tablet has 1 mg of Finasteride USP. The typical adult dosage is one tablet per day. However, women and children should not use these tablets. Pregnant women should avoid using them, and there should be no contact with crushed or broken Finasteride tablets. The tablets must be stored in controlled room temperature in a tight container, without direct exposure to light or moisture. This batch of Finasteride tablets is manufactured by Cipla Ltd. in India and distributed by Cipla USA in Florida, USA. The remaining text contains details about overprinting for batch identification.*